ENTPD1 and acute myeloid leukemia: CD39 cell-surface expression and activity is increased in patients with acute myeloid leukemia (AML) upon chemotherapy compared with diagnosis, and enrichment in CD39-expressing blasts is a marker of adverse prognosis in the clinic (130).